AstraZeneca inks more R&D collaborations; GSK races to FDA with melanoma combo; Acorda inks $8M deal;

@FierceBiotech: 'Fraud' found at China site for key study of Pfizer and Bristol's Eliquis. Report | Follow @FierceBiotech

 @JohnCFierce: Amgen commits $50M-plus in 3-way deal to expand cardiovascular drug pipeline. Article | Follow @JohnCFierce

@RyanMFierce: Expert exposes "highly questionable" data from biotech Cardio3 after IPO. ICYMI yesterday | Follow @RyanMFierce

> AstraZeneca ($AZN) won't be moving into its new HQ and research complex in Cambridge for another three years, but it's already building early-stage research ties in the region in the transition period. The pharma giant announced new research pacts with the University of Cambridge and Cancer Research UK Cambridge Institute on a new combo treatment for prostate cancer that adds AZD2014 to the experimental olaparib. And several Cambridge groups will work collaboratively onm new therapies for pancreatic cancer. Story

> GlaxoSmithKline ($GSK) has raced to regulators with an application to sell a combination of dabrafenib and trametinib for melanoma. The Big Pharma company is using Phase I/II data rather than waiting for late-stage results, expecting that regulators will be warmly receptive to early-stage data from a match of two drugs which are approved separately. Story

> Acorda ($ACOR) has nabbed two neuropathic pain therapies from NeurogesX ($NGSK): Qutenza and NP-1998. Qutenza is approved for neuropathic pain associated with postherpetic neuralgia while NP-1998 is a Phase III-ready capsaicin topical solution. Acorda paid about $8 million in the deal. Release

> Omthera Pharmaceuticals ($OMTH), which is being acquired by AstraZeneca ($AZN), has filed its NDA for the omega-3 drug Epanova. Release

Medical Device News

@FierceMedDev: New special report: A look at 2013's hot M&A start. Feature | Follow @FierceMedDev

 @MarkHFierce: It's not easy for Dx outfits to win Medicare coverage in today's market, but Crescendo did. Story | Follow @MarkHFierce

@DamianFierce: Are Intuitive's weak da Vinci sales a hiccup or an omen? Shares slipped 15% overnight. News | Follow @DamianFierce

> Diagnostic device detects bladder cancer through urine odor. Article

> Tyrx gains FDA clearance for dissolvable antibacterial envelope. Story

> Denmark wants EU ban on chemical used in device manufacturing. More

Pharma News

@FiercePharma: Investors hiss at Pharmstandard spinoff engineering. Plans to buy out investors who oppose OTC deal--at a discount. More | Follow @FiercePharma

 @CarlyHFierce: Alleged Botox marketing strategy in China named for Russian sniper Vasily Zaytsev - anyone seen Enemy at the Gates? More (sub. req.) | Follow @CarlyHFierce

> If Allergan went on the block, would Big Pharma bite? More

> Mylan's $1.6B Agila buyout hits snag in India amid cancer drug worries. Report

> Alzheimer's group pledges fight for Lilly's Amyvid. Article

Pharma Manufacturing News

 @EricPFierce: I'm looking for pharma folks interested in being part of a webinar on how their companies are using marketing apps to talk with clients. Let me know. | Follow @EricPFierce

> Nikkei: Teva to double manufacturing capacity in Japan. More

> Wockhardt faces 2nd import alert. Report

> Hikma New Jersey plant back in production. Article

> Fresenius gets 2nd warning letter in 18 months. Story

Biotech Research News

 @EmilyMFierce: Ohio-based startup Biosortia is tapping into nature to fill early drug-discovery void. Editor's corner | Follow @EmilyMFierce

> U.K. launches large-scale genomics project. More

> Immune modulation could explain how experimental Alzheimer's therapy works. Item

> More positive preclinical results for Inovio's H7N9 vaccine. Story

> New research could help cut cardiovascular risks associated with arthritis drugs. Article